MR Microimaging of amyloid plaques in Alzheimer's disease transgenic mice

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue SUPPL. 1, 2008, Pages

  Wengenack, Thomas M ^a   Jack Jr , Clifford R ^a   Garwood, Michael ^b   Poduslo, Joseph F ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Magnetic resonance imaging; Plaque; Transgenic mouse

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMYLOID BETA PROTEIN[1-40]; AMYLOID PROTEIN; CONTRAST MEDIUM; GADOLINIUM; IODINE 125; PENTETIC ACID;

ALZHEIMER DISEASE; BRAIN; CONTRAST ENHANCEMENT; DISEASE MARKER; IMAGING; IN VIVO STUDY; MEMORY; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; MOLECULAR PROBE TECHNIQUES; SENILE PLAQUES;

EID: 41149130103     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0706-9     Document Type: Review

References (27)

1. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002;11:315-29.
2. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24-35.
3. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, et al. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003;50:293-302.
4. Jack CR Jr., Garwood M, Wengenack TM, Borowski BJ, Curran GL, Lin J, et al. In vivo visualization of Alzheimer's amyloid plaques by MRI in transgenic mice without a contrast agent. Magn Reson Med 2004;52:1263-71.
5. Jack CR Jr., Wengenack TM, Reyes DA, Garwood M, Curran GL, Borowski BJ, et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci 2005;25:10041-8.
6. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
7. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004;12:584-95.
8. Falangola MF, Lee SP, Nixon RA, Duff K, Helpern JA. Histological co-localization of iron in A-beta plaques of PS/APP transgenic mice. Neurochem Res 2005;30:201-5.
9. Vanhoutte G, Dewachter I, Borghgraef P, Van Leuven F, Van der Linden A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn Reson Med 2005;53:607-13.
10. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100.
11. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
12. Wengenack TM, Whelan SL, Curran GL, Duff KE, Poduslo JF. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neurosci 2000a;101:939-44.
13. Robb RA. A software system for interactive and quantitative analysis of biomedical images. In: Hohne KH, Fuchs H, Pizer SM, editors. 3D imaging in medicine. vol 60. Berlin-Heidelberg: Springer Verlag; 1990. p. 333-61.
14. LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 1997;760:298-303.
15. Benveniste H, Einstein G, Kim KR, Hulette C, Johnson GA. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci U S A 1999;96:14079-84.
16. 2 *- weighted MR microscopic images. NMR Biomed 2002;15:197-203.
17. LeVine SM. Oligodendrocytes and myelin sheaths in normal, quaking, and shiverer brains are enriched in iron. J Neurosci 1991;29:413-9.
18. Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, et al. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci U S A 1992;89(12):5462-6.
19. Ghilardi JR, Catton M, Stimson ER, Rogers S, Walker LC, Maggio JE, et al. Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 1996;7(15-17):2607-11.
20. Poduslo JF, Curran GL. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J Neurochem 1996;66:1599-609.
21. Wengenack TM, Curran GL, Poduslo JF. Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 2000b;18(8):868-72.
22. Wengenack TM, Curran GL, Poduslo JF. Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia. Brain Res 1997;754(1-2):46-54.
23. Poduslo JF, Curran GL, Gill JS. Putrescine-modified nerve growth factor: bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution. J Neurochem 1998;71(4):1651-60.
24. Reinholz MM, Merkle CM, Poduslo JF. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp Neurol 1999;159(1):204-16.
25. Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, Khan MA, et al. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochem 2004;43(20):6064-75.
26. Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci U S A 1994;91:5705-9.
27. Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ, et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 2007;102(2):420-33.